Format

Send to

Choose Destination
AIDS. 2015 Jul 31;29(12):1467-71. doi: 10.1097/QAD.0000000000000737.

Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.

Author information

1
aUniversity of Washington bSeattle Children's Research Institute, Seattle, Washington, USA cInstitut de Recherche pour le Développement (IRD) UMI 174-PHPT, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand dHarvard School of Public Health, Boston, Massachusetts eTulane University School of Medicine, New Orleans, Louisiana, USA.

Abstract

To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDV-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%). These data raise the question whether women administered ZDV monotherapy for prevention of mother-to-child-transmission could have higher risk of virologic failure when later started on combination antiretroviral therapy, as has been demonstrated following single-dose nevirapine prophylaxis.

PMID:
26244386
PMCID:
PMC4618483
DOI:
10.1097/QAD.0000000000000737
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center